Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: J Pediatr. 2023 Apr 4;258:113409. doi: 10.1016/j.jpeds.2023.113409

Table 2.

Base case population-level results1 for HCV testing strategies among a cohort of infants, United States, 2022

Testing among known exposed2
 Universal testing of all infants
Outcome Anti-HCV with
reflex to HCV RNA
at 18 months3
(Comparison)		 HCV RNA test at
2–6 months4
(Test Strategy 1)		 Anti-HCV with reflex
to HCV RNA at 18
months3,5
(Test Strategy 2)		 HCV RNA test at
2–6 months4,6
(Test Strategy 3)
Total costs (2021 USD) 77,621,446 77,151,775 116,433,899 207,170,025
Testing outcomes
 Tested infants 4,478 7,588 2,709,916 3,076,918
 Anti-HCV tests 4,478 0 2,709,916 0
 HCV RNA tests 330 7,588 6,120 3,076,918
Epidemiologic outcomes among perinatally exposed infants
 Diagnosed HCV infections 254 443 553 971
 Hepatocellular carcinoma cases 419 342 316 151
 Decompensated cirrhosis cases 463 388 334 157
 Liver transplants 74 62 58 28
 HCV Liver-related deaths 758 626 550 259
 Treated/cured HCV infections 196 347 438 775
 Total QALYs 693,059 694,026 694,546 696,669
 Total Life-years 1,807,109 1,812,187 1,814,939 1,826,061
1

Assumes 3.6 million births with 0.64% of births occurring among persons who are HCV RNA+.

2

Assumes 44.7% of all pregnant persons are screened for HCV infection.

3

Assumes 43.0% of infants born to HCV RNA+ pregnant persons attend an 18-month visit.

4

Assumes 73.5% of infants born to HCV RNA+ pregnant persons attend a 2–-6 month visit.

5

Assumes 75.0% of infants born to pregnant persons without HCV attend an 18-month visit.

6

Assumes 85.0% of infants born to pregnant persons without HCV attend a 2–6 month visit.

Abbreviations: HCV, hepatitis C virus; anti-HCV, hepatitis C virus antibody; USD, United States Dollars; QALYs, quality-adjusted life-years.